PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-41.82%
Cash & equivalents declining -41.82% while Medical - Pharmaceuticals shows 2.30% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-41.82%
Below half the Medical - Pharmaceuticals median of 1.25% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
-1.61%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
-6.17%
Inventory growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
-6.06%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-15.44%
Below half the Medical - Pharmaceuticals median of 1.89%. Jim Chanos would question if the company faces working capital strain.
3.34%
PP&E growth below half of Medical - Pharmaceuticals median of -0.35%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-4.86%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
-83.22%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
No Data
No Data available this quarter, please select a different quarter.
2233500.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
3.18%
≥ 1.5x the Medical - Pharmaceuticals median of 0.96%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-2.56%
Below half the Medical - Pharmaceuticals median of 1.77%. Jim Chanos might see potential stagnation or distress vs. peers.
-9.84%
Payables growth below half of Medical - Pharmaceuticals median of 2.54%. Joel Greenblatt sees more conservative payables management vs. peers.
84.85%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.09%
Below half Medical - Pharmaceuticals median of 5.77%. Joel Greenblatt sees fewer expansions than peers.
-8.07%
Below half Medical - Pharmaceuticals median of 2.27%. Joel Greenblatt sees more conservative short-term leverage than peers.
-3.85%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.02%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-2.12%
Above 1.5x Medical - Pharmaceuticals median of -0.34%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-7.33%
Below half Medical - Pharmaceuticals median of 1.35%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
2.28%
Below half Medical - Pharmaceuticals median of -0.37%. Jim Chanos suspects poor profitability or large dividend drains.
-3.09%
AOCI growth below half of Medical - Pharmaceuticals median 0.59%. Joel Greenblatt sees fewer exposures vs. peers.
100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
2.19%
≥ 1.5x Medical - Pharmaceuticals median of 1.28%. Joel Greenblatt sees stronger equity growth vs. peers.
-2.56%
Below half Medical - Pharmaceuticals median of 1.77%. Jim Chanos suspects a major slowdown or distress.
-83.22%
≥ 1.5x Medical - Pharmaceuticals median of -0.26%. Joel Greenblatt sees bigger push into investments vs. peers.
11.12%
Below half Medical - Pharmaceuticals median of -1.90%. Joel Greenblatt sees a stronger deleveraging trend than peers.
142.84%
Below half of Medical - Pharmaceuticals median -3.91%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.